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BackgroundThere have been conflicting reports on the efficacy of recombinant
human activated protein C, or drotrecogin alfa (activated) (DrotAA), for the
treatment of patients with septic shock. Methods In this randomized, double-blind,
placebo-controlled, multicenter trial, we assigned 1697 patients with infection,
systemic inflammation, and shock who were receiving fluids and vasopressors above
a threshold dose for 4 hours to receive either DrotAA (at a dose of 24 μg per
kilogram of body weight per hour) or placebo for 96 hours. The primary outcome was
death from any cause 28 days after randomization. Results At 28 days, 223 of 846
patients (26.4%) in the DrotAA group and 202 of 834 (24.2%) in the placebo group
had died (relative risk in the DrotAA group, 1.09; 95% confidence interval [CI], 0.92
to 1.28; P=0.31). At 90 days, 287 of 842 patients (34.1%) in the DrotAA group and
269 of 822 (32.7%) in the placebo group had died (relative risk, 1.04; 95% CI, 0.90 to
1.19; P=0.56). Among patients with severe protein C deficiency at baseline, 98 of
342 (28.7%) in the DrotAA group had died at 28 days, as compared with 102 of 331
(30.8%) in the placebo group (risk ratio, 0.93; 95% CI, 0.74 to 1.17; P=0.54).
Similarly, rates of death at 28 and 90 days were not significantly different in other
predefined subgroups, including patients at increased risk for death. Serious
bleeding during the treatment period occurred in 10 patients in the DrotAA group
and 8 in the placebo group (P=0.81). Conclusions DrotAA did not significantly
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